Dasotraline promising for the treatment of ADHD in children

Dasotraline promising for the treatment of ADHD in children

(HealthDay)—Treatment with dasotraline (4 mg/day) significantly improves attention-deficit/hyperactivity disorder (ADHD) symptoms in children aged 6 to 12 years, according to a study published online March 7 in the Journal of Child and Adolescent Psychopharmacology.

Robert L. Findling, M.D., from Johns Hopkins University in Baltimore, and colleagues randomly assigned 342 children diagnosed with ADHD (mean age, 9.1 years; 66.7 percent male) to six weeks of once-daily treatment with either dasotraline (2 or 4 mg) or .

The researchers found that treatment with dasotraline 4 mg/day was associated with significant improvement in the ADHD Rating Scale Version IV-Home Version total score versus placebo, but the 2-mg/day dose was not. The dasotraline 4-mg/day dose was also associated with significant improvement versus placebo for the Clinical Global Impression-Severity scale, the Conners' Parent Rating Scale-Revised ADHD index score, and subscale measures of hyperactivity and inattentiveness. However, the dasotraline 4-mg/day group had higher discontinuation rates due to compared with the 2-mg/day group (12.2 and 6.3 percent, respectively, versus 1.7 percent for placebo). Insomnia, decreased appetite, decreased weight, and irritability were the most common adverse events associated with dasotraline. Psychosis-related symptoms were reported by seven of 219 patients taking dasotraline.

"The results of the current study provide efficacy and safety data indicating that dasotraline, dosed once-per-day, is a promising therapeutic option for the treatment of ADHD, with a reduced potential for abuse, and with a long elimination half-life permitting sustained efficacy across a 24-hour dosing interval," the authors write.

Several authors disclosed financial ties to , including Sunovion, which manufactures dasotraline and funded the study.

Explore further

Researchers report positive findings with dasotraline for ADHD in children ages 6-12

More information: Abstract/Full Text

Copyright © 2019 HealthDay. All rights reserved.

Citation: Dasotraline promising for the treatment of ADHD in children (2019, March 8) retrieved 23 July 2019 from https://medicalxpress.com/news/2019-03-dasotraline-treatment-adhd-children.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments

Mar 09, 2019
ooh another drug for the kiddies

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more